Shanghai, China, May 25, 2023 – TYK Medicines, Inc. (hereinafter referred to as TYK Medicines) and WuXi STA (A subsidiary of WuXi AppTec) jointly announced the establishment of a comprehensive strategic partnership for integrated CMC services. The signing ceremony was attended by Dr. Yusheng Wu, Chairman of TYK Medicines, Dr. Shaoqing Chen, Senior Vice President of TYK Medicines, Dr. Xiaoyong Fu, Senior Vice President of WuXi AppTec and Head of API Business Unit at WuXi STA, and Dr. Jinling Chen, Senior Vice President of WuXi AppTec and Head of Formulation Business Unit at WuXi STA.

TYK Medicines focuses on the discovery of new-generation kinase inhibitors to address the unmet medical needs in cancer therapy. TYK Medicines has a diversified pipeline with 10+ compounds including multiple phases from the PCC stage to Phase III clinical trial. Previously, TYK Medicines and WuXi STA had business cooperation on multiple projects, covering areas such as API, formulation research and development, manufacturing, and the preparation of IND application materials for both China and the United States. The two companies have decided to expand their research and development pipeline and engage in more comprehensive cooperation based on the rapid progress achieved in multiple collaborative projects.

As a leading CRDMO company, WuXi STA has successfully supported 38 innovative drugs from its partners since 2017, with these new drugs being marketed in 105 countries worldwide. According to the strategic cooperation agreement, WuXi STA will become the strategic partner of TYK Medicines in the CRDMO field, providing one-stop services of API, formulation research and development, clinical trial, commercial manufacturing, and preparation of IND applications for both China and the United States for the current and subsequent pipelines.

Dr. Yusheng Wu, Chairman of TYK Medicines, stated, “TYK Medicines has developed a series of competitive product pipelines, while WuXi STA has industry-leading platform capabilities and rich experience in supporting the successful market launch of new drugs. We believe that our deep cooperation will further accelerate the development progress of TYK Medicines’ product pipelines, enabling the early launch of innovative drugs to benefit cancer patients.”

Dr. Minzhang Chen, the joint CEO of WuXi AppTec and CEO of WuXi STA, stated, “It was a pleasure to open a new chapter in our deep cooperation with TYK Medicines. We will continue to leverage the integrated CRDMO platform from WuXi STA, as well as the quality system which complies with international standards to provide favorable support for TYK Medicines’ innovative drug pipelines at different stages, benefiting patients globally.”

About TYK Medicines, Inc.

TYK Medicines, Inc. is an innovative biopharmaceutical company founded by MNC veterans in 2017, focusing on the discovery of new-generation Kinase Inhibitors to address the unmet medical needs in cancer therapy. TYK Medicines has a diversified pipeline with 10+ compounds including multiple phases from the PCC stage to Phase III clinical trial. The company is committed to providing patients with more effective and safer anti-tumor drugs. For more company information, please visit: www.tykmedicines.com

About WuXi STA (Shanghai) Co., Ltd

WuXi STA, a subsidiary of WuXi AppTec, is an industry-leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry with operations across Asia, North America, and Europe. As an innovative Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi STA offers our worldwide partners efficient, flexible, and high-quality solutions for integrated CMC (Chemical, Manufacturing, and Controls) solutions from preclinical to commercial uses, including the development and manufacturing of small molecule, oligonucleotide, peptide and various complex chemical conjugate.. For more company information, please visit: www.stapharma.com